Artiva Ends AlloNK Development After Risk Benefit Review

Company Artiva Biotherapeutics Event Type Program discontinuation and restructuring Modality Allogeneic non-engineered NK-cell therapy plus rituximab Asset AlloNK (AB-101) Target B-cell depletion (with anti-CD20) Disease Area Rheumatoid arthritis and other autoimmune disease Summary Artiva announced on 27 October that it will stop all AlloNK clinical…